{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:59:26Z","timestamp":1791273566453,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2017.10.017","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T21:01:35Z","timestamp":1508014895000},"page":"82-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"PA","title":["Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature"],"prefix":"10.1016","volume":"134","author":[{"given":"Patil","family":"Armenian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Darracq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirair","family":"Gevorkyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicklaus P.","family":"Brandehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa1610300","article-title":"\u201cZombie\u201d outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York","volume":"376","author":"Adams","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.017_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1021\/ja01182a068","article-title":"Tetrahydrocannabinol homologs","volume":"70","author":"Adams","year":"1948","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib3","first-page":"639","article-title":"Ease of purchasing popular \u201cresearch chemicals\u201d via the internet","volume":"53","author":"Armenian","year":"2015","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.017_bib5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jms.1558","article-title":"'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?","volume":"44","author":"Auw\u00e4rter","year":"2009","journal-title":"J.\u00a0Mass Spectrom."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/acschemneuro.5b00112","article-title":"Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB- PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA","volume":"6","author":"Banister","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.forsciint.2014.04.020","article-title":"Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine","volume":"241","author":"Barnes","year":"2014","journal-title":"Forensic Sci. Int."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.017_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/FTD.0000000000000201","article-title":"Validation of an ELISA synthetic cannabinoids urine assay","volume":"37","author":"Barnes","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3109\/15563650.2011.635149","article-title":"2010 annual report of the american association of poison control centers' National Poison Data system (NPDS): 28th annual report","volume":"49","author":"Bronstein","year":"2011","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650.2012.746424","article-title":"2011 annual report of the american association of poison control centers' National Poison Data system (NPDS): 29th annual report","volume":"50","author":"Bronstein","year":"2012","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.drugalcdep.2014.07.009","article-title":"Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates","volume":"143","author":"Bonar","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib13","series-title":"The DAWN Report: drug-related emergency department visits involving synthetic cannabinoids","author":"Center for Behavioral Health Statistics and Quality","year":"2012"},{"issue":"6","key":"10.1016\/j.neuropharm.2017.10.017_bib14","first-page":"93","article-title":"Acute kidney injury associated with synthetic cannabinoid use\u2013multiple states, 2012","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"49","key":"10.1016\/j.neuropharm.2017.10.017_bib15","first-page":"1016","article-title":"Notes from the field: severe illness associated with reported use of synthetic marijuana - Colorado, August-September 2013","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib16","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1523\/JNEUROSCI.0529-04.2004","article-title":"Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats","volume":"24","author":"Cheer","year":"2004","journal-title":"J.\u00a0Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bcp.12720","article-title":"Treatment of drug-induced seizures","volume":"81","author":"Chen","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0006-8993(93)90298-2","article-title":"Ventral tegmental microinjection of delta 9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: evidence for local neural action by marijuana's psychoactive ingredient","volume":"621","author":"Chen","year":"1993","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.neuropharm.2017.10.017_bib19","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1124\/dmd.112.047530","article-title":"Cytochrome P450-Mediated oxidative metabolism of abused synthetic cannabinoids found in K2\/Spice: identification of novel cannabinoid receptor ligands","volume":"40","author":"Chimalakonda","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jpeds.2015.06.001","article-title":"Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients","volume":"167","author":"Clark","year":"2015","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11920-016-0694-1","article-title":"Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal","volume":"18","author":"Cooper","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/SAR.S73586","article-title":"Emerging drugs of abuse: current perspectives on synthetic cannabinoids","volume":"6","author":"Debruyne","year":"2015","journal-title":"Subst. Abuse Rehab"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.017_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pnpbp.2012.07.011","article-title":"Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project","volume":"39","author":"Deluca","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"46","key":"10.1016\/j.neuropharm.2017.10.017_bib24","first-page":"939","article-title":"Notes from the field: severe illness associated with synthetic cannabinoid use \u2014 Brunswick, Georgia, 2013","volume":"62","author":"Drenzek","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"40","key":"10.1016\/j.neuropharm.2017.10.017_bib25","first-page":"11075","article-title":"Department of justice. Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I","volume":"76","author":"Drug Enforcement Administration (DEA)","year":"2011","journal-title":"Fed. Regist."},{"issue":"95","key":"10.1016\/j.neuropharm.2017.10.017_bib26","first-page":"28735","article-title":"Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order","volume":"78","author":"Drug Enforcement Administration (DEA)","year":"2013","journal-title":"Fed. Regist."},{"issue":"27","key":"10.1016\/j.neuropharm.2017.10.017_bib27","first-page":"7577","article-title":"Department of Justice. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order","volume":"79","author":"Drug Enforcement Administration (DEA)","year":"2014","journal-title":"Fed. Regist."},{"issue":"20","key":"10.1016\/j.neuropharm.2017.10.017_bib28","first-page":"5042","article-title":"Department of Justice. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into schedule I. Final order","volume":"80","author":"Drug Enforcement Administration","year":"2015","journal-title":"Fed. Regist."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib29","series-title":"EMCDDA 2009 Thematic Paper\u2014Understanding the \u2018Spice\u2019 Phenomenon","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2009"},{"key":"10.1016\/j.neuropharm.2017.10.017_bib30","unstructured":"Federal Analogue Act, 21 U.S.C. 813. 99th Unites States Congress. Effective October 27, 1986."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/dta.1662","volume":"7","author":"Gandhi","year":"2015","journal-title":"Drug Test. Anal."},{"issue":"10","key":"10.1016\/j.neuropharm.2017.10.017_bib32","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00213-016-4237-6","article-title":"\u03949-Tetrahydrocannabinol-Like effects of novel synthetic cannabinoids in mice and rats","volume":"233","author":"Gatch","year":"2016","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.017_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jemermed.2012.07.061","article-title":"Synthetic cannabinoid intoxication: a case series and review","volume":"44","author":"Harris","year":"2013","journal-title":"J.\u00a0Emerg. Med."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib34","article-title":"2011 Health related behaviors survey of active duty military personnel","author":"Jeffrey","year":"2013","journal-title":"Dep. Def."},{"issue":"39","key":"10.1016\/j.neuropharm.2017.10.017_bib35","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.15585\/mmwr.mm6439a7","article-title":"Notes from the field: severe illness associated with reported use of synthetic cannabinoids \u2014 Mississippi, April 2015","volume":"64","author":"Kasper","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"15","key":"10.1016\/j.neuropharm.2017.10.017_bib36","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1007\/s00216-013-7574-x","article-title":"LC-QTOF-MS as a superior strategy to immunoassay for the comprehensive analysis of synthetic cannabinoids in urine","volume":"406","author":"Kronstrand","year":"2014","journal-title":"Anal. Bioanal. Chem."},{"issue":"22","key":"10.1016\/j.neuropharm.2017.10.017_bib37","first-page":"618","article-title":"Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use \u2014 United States, January\u2013may 2015","volume":"64","author":"Law","year":"2015","journal-title":"MMWR Morb. Mort Wkly. Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.017_bib38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cpt.563","article-title":"Focus on cannabinoids and synthetic cannabinoids","volume":"101","author":"Le Boisselier","year":"2017","journal-title":"Clin Pharm Ther."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainresbull.2016.04.013","article-title":"International trends in spice use: prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids","volume":"126","author":"Loeffler","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.017_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13181-014-0424-1","article-title":"K2\u2014not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report","volume":"11","author":"McKeever","year":"2015","journal-title":"J.\u00a0Med. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fnins.2016.00153","article-title":"Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants","volume":"10","author":"Miliano","year":"2016","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2017.10.017_bib42","doi-asserted-by":"crossref","first-page":"e1622","DOI":"10.1542\/peds.2010-3823","article-title":"Myocardial infarction associated with use of the synthetic cannabinoid K2","volume":"128","author":"Mir","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.neuropharm.2017.10.017_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMc1313655","article-title":"An outbreak of exposure to a novel synthetic cannabinoid","volume":"370","author":"Monte","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2017.10.017_bib44","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1021\/ac2005636","article-title":"Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine","volume":"83","author":"Moran","year":"2011","journal-title":"Anal. Chem."},{"issue":"10","key":"10.1016\/j.neuropharm.2017.10.017_bib45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1080\/15563650.2016.1245421","article-title":"2015 annual report of the american association of poison control centers' National Poison Data system (NPDS): 33rd annual report","volume":"54","author":"Mowry","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.017_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11419-015-0270-0","article-title":"Comprehensive review of the detection methods for synthetic cannabinoids and cathinones","volume":"33","author":"Namera","year":"2015","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.drugalcdep.2015.01.044","article-title":"Synthetic cannabinoid use in a nationally representative sample of US high school seniors","volume":"149","author":"Palamar","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.neuropharm.2017.10.017_bib48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.15585\/mmwr.mm6527a2","article-title":"Acute poisonings from synthetic cannabinoids \u2014 50 U.S. Toxicology investigators consortium registry sites, 2010\u20132015","volume":"65","author":"Riederer","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"5","key":"10.1016\/j.neuropharm.2017.10.017_bib50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jemermed.2014.12.038","article-title":"A\u00a0common source outbreak of severe delirium associated with exposure to the novel synthetic cannabinoid ADB-PINACA","volume":"48","author":"Schwartz","year":"2015","journal-title":"J.\u00a0Emerg. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2017.10.017_bib51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/dta.1702","article-title":"Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids","volume":"7","author":"Spinelli","year":"2015","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib52","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.15585\/mmwr.mm6540a4","article-title":"Increase in adverse reactions associated with use of synthetic cannabinoids \u2014 anchorage, Alaska, 2015\u20132016","volume":"65","author":"Springer","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib53","unstructured":"Synthetic Drug Abuse Prevention Act of 2012. S. 3190, 112th Congress, 2nd Session."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.017_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/15563650.2015.1110590","article-title":"A\u00a0systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib55","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/dta.1731","article-title":"Synthetic cannabimimetic agents metabolized by carboxylesterases","volume":"7","author":"Thomsen","year":"2015","journal-title":"Drug Test. Anal."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.annemergmed.2015.05.021","article-title":"Unintentional pediatric exposure to a synthetic cannabinoid (AB-PINACA) resulting in coma and intubation","volume":"66","author":"Thornton","year":"2015","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib57","series-title":"Global SMART Update Volume 13","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.10.017_bib58","series-title":"United States Court of Appeals, Eighth Circuit","author":"United States of America, v","year":"2002"},{"issue":"6","key":"10.1016\/j.neuropharm.2017.10.017_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3109\/15563650.2016.1171329","article-title":"Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service","volume":"54","author":"Waugh","year":"2016","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib60","series-title":"Hijacking of Basic Research; the Case of Synthetic Cannabinoids","author":"Wiley","year":"2011"},{"key":"10.1016\/j.neuropharm.2017.10.017_bib61","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.115.225326","article-title":"AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing d9-tetrahydrocannabinol\u2013like effects in mice","volume":"354","author":"Wiley","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib62","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1208\/s12248-015-9721-0","article-title":"Pentylindole\/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA","volume":"17","author":"Wohlfarth","year":"2015","journal-title":"AAPS J."},{"issue":"3","key":"10.1016\/j.neuropharm.2017.10.017_bib63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1515\/cclm-2014-0612","article-title":"Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS\/MS targets to document synthetic cannabinoid intake in US military urine specimens","volume":"53","author":"Wohlfarth","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2017.10.017_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-2069.171400","article-title":"Chest pain, troponin rise, and ST-elevation in an adolescent boy following the use of the synthetic cannabis produce K2","volume":"9","author":"Zaleta","year":"2016","journal-title":"Ann. Pediatr. Cardiol."},{"key":"10.1016\/j.neuropharm.2017.10.017_bib65","first-page":"464","article-title":"Withdrawal phenomena and dependence syndrome after the consumption of \u201cSpice Gold\u201d","volume":"106","author":"Zimmermann","year":"2009","journal-title":"Dtsch. Arztebl Int."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T22:28:58Z","timestamp":1535322538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":65,"alternative-id":["S0028390817304835"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.017","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}